I found this an informative and well-designed observational study, using a large data set and appropriate analytical methods. As a researcher in the field I believe contains valuable information, however, I do not believe it is of sufficient general interest for the BMJ and would be more suited to AD journal such as JAD or a clinical trials journal. I have a few general comments. The manuscript would be improved by some discussion of the generalizability of their findings beyond France. It would be unusual for a Drug Trial to be performed in a single country. Discussing their results in terms of multinational setting a multinational would be of interest.
Such details regarding the lumbar puncture are unnecessary.
The manuscript would benefit from some discussion with regard to the potential impact on amyloid imaging and an expansion of their imaging discussion in general.
The manuscript would benefit from more detail and discussion with regards to the measurement of vascular burden and consequent diagnosis of mixed dementia. The text "The presence of significant vascular lesions on MRI (at the discretion of the clinicians)" tells us little. No one grows old without some vascular change. A more vigorous approach hear would be essential and overzealous exclusion here may well be the reason for these observations. 3) The discussion is nice, but I would recommend emphasizing or expanding the generalizability argument, points 4 and 5. I think one of the main arguments in the paper is that even in a wellorganized medical system like France, the types of participants studied in clinical trials have a very specific type of AD, and per the paper, appear rare (don't get the testing or are not identified on time or are a small percentage of overall AD patients). This could have major implications if a disease modifying therapy is approved. 4) A simple illustration or flow diagram would aide people who are not familiar with the French system. I think this could be placed in section 2.1.
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Please state any competing interests or state 'None declared': None Please leave your comments for the authors below How many patients are eligible for disease modifying treatment in Alzheimer's disease? A French national study over five years I found this an informative and well-designed observational study, using a large data set and appropriate analytical methods.
R: We thank Reviewer 1 for this positive set of comments.
As a researcher in the field I believe contains valuable information, however, I do not believe it is of sufficient general interest for the BMJ and would be more suited to AD journal such as JAD or a clinical trials journal. R: We beg to disagree with this statement for two main reasons: firstly the Alzheimer's disease field is broad and encompass many fields by itself (from social science to clinical and preclinical research) and is the focus of a rising tide of studies worldwide (especially regarding therapeutic trials which is the area under the most scrutiny). Secondly, the development and use of a nationwide database to analyze the incidence of public health threats such as Alzheimer's disease can appeal to a much wider community (perhaps to all clinicians interested by chronic diseases).
I have a few general comments.
The manuscript would be improved by some discussion of the generalizability of their findings beyond France. It would be unusual for a Drug Trial to be performed in a single country. Discussing their results in terms of multinational setting a multi-national would be of interest.
R: We fully agree with reviewer N°1 that our study, so far and to our knowledge, cannot be generalized to other countries because we lack recent epidemiological data on Alzheimer's disease on the same scale as our study. Results from these studies 1 are usually derived from cohorts recruited in the 1990s' or 2000s' and not these last years. This fact alone is troublesome both because of the suggested trend in AD incidence decrease these last decades 2 3 and because the recruitment in these cohorts predates the newest diagnostic criteria for AD 4-6. Finally, early AD is never individualized in these studies focusing on AD whatever the severity at diagnosis. Also, the use of biomarkers is never disclosed in these epidemiological studies. All of this is now emphasized at the end of the discussion.
R: This paragraph has been simplified.
R: The impact of amyloid imaging and amyloid assessment by blood sampling are now briefly described in the discussion.
The manuscript would benefit from more detail and discussion with regards to the measurement of vascular burden and consequent diagnosis of mixed dementia. The text "The presence of significant vascular lesions on MRI (at the discretion of the clinicians)" tells us little. No one grows old without some vascular change. A more vigorous approach hear would be essential and overzealous exclusion here may well be the reason for these observations. R: the non-inclusion criteria for vascular lesions on MRI were as follows: Fazekas and Schmidt leukopathy stage 3 or presence of at least one lacunar or territorial infarct or supracentimetric brain hemorrhagic sequalae. This is now more clearly stated in the methods section. We emphasized the "zealousness" of this exclusion criteria in the discussion as we fully agree with Reviewer N°1 that this criteria will severely limit the broad application of a disease modifying treatment, should one become available in the coming years. 2) Lines 238-240 are a little ambiguous. Only 16.3% of people with LP fit criteria for early AD. Is this because only a small percentage had AD or was it of other reasons (i.e. their MMSE was too low, FCSRT was too high). The way its written it could be interpreted that only 16.3% of suspected AD actually had confirmatory Abeta to tau ratios (which seems very low), meaning they had other diagnoses. I am assuming the former, that there was a lot of AD results but only 16.3 met clinical trial criteria.
R: We thank Reviewer N°2 for this comment. We now describe more precisely the percentages of patients with LP. In fact, 16,3% of participants had an "early AD" diagnosis per our chosen criteria, 26,7 % had a diagnosis of AD with a MMSE below 20; 2.1% had a diagnosis of AD with a MMSE over 20 but a FCSRT with subscores over our chosen thresholds; 30.2% had a mixed dementia profile (AD and vascular lesions 65%; AD and suspected Lewy body dementia 23%; AD and other 12%) and finally 24.7% had another diagnosis (not AD). This is now stated in the result section of the manuscript. Unfortunately, as these groups were excluded from further analysis, we did not collect data from their participants.
3) The discussion is nice, but I would recommend emphasizing or expanding the generalizability argument, points 4 and 5. I think one of the main arguments in the paper is that even in a wellorganized medical system like France, the types of participants studied in clinical trials have a very specific type of AD, and per the paper, appear rare (don't get the testing or are not identified on time or are a small percentage of overall AD patients). This could have major implications if a disease modifying therapy is approved. R: We thank reviewer N°2 for this comment that is related to comment N°5 from reviewer N°1 and has been addressed above.
